Summit Securities Group’s BridgeBio Pharma BBIO Stock Holding History

Summit Securities Group’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-383	Closed	-$13.2K	–	1094
2025 Q1	$13.2K	Buy	+383	New	+$12.9K	﹤0.01%	520
2024 Q4	–	Sell	-368	Closed	-$9K	–	640
2024 Q3	$9K	Buy	+368	New	+$9.66K	﹤0.01%	383
2023 Q2	–	Sell	-2,000	Closed	-$33K	–	881
2023 Q1	$33K	Buy	+2,000	New	+$23.3K	﹤0.01%	517

Other funds holding BBIO

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Summit Securities Group's BBIO Position: Q2 2025 in Review

Summit Securities Group sold out of BridgeBio Pharma (BBIO) in Q2 2025, closing a stake of 383 shares — an estimated $13.2K sold.

Summit Securities Group first reported a position in BBIO in Q1 2023 and held it in 3 quarters. The position peaked at $33K in Q1 2023. 359 funds tracked by Wall St. Rank hold BBIO as of Q2 2025.

Summit Securities Group reported no remaining BridgeBio Pharma position as of Q2 2025 after selling out during the quarter.
Summit Securities Group sold 383 BridgeBio Pharma shares in Q2 2025, an estimated $13.2K.
Summit Securities Group first reported a position in BridgeBio Pharma in Q1 2023 and held it in 3 quarters.
Summit Securities Group's BridgeBio Pharma position peaked at $33K in Q1 2023.
359 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2025.

Based on Summit Securities Group's 13F filing for Q2 2025, filed 12 Aug 2025.